Recommended

Amgen secures Uplizna EU approval in gMG
Orsellinic acid study demonstrates production first
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
J&J to site new $1bn cell therapy facility in Pennsylvania
FDA sets new default standard for US drug approvals
Daiichi Sankyo picks new Global Head of R&D
Dr Belén Garijo replaces Paul Hudson as Sanofi CEO
Discover how to harness digital PCR for rapid sterility testing
news

NICE and Canadian Agency collaborate to offer parallel scientific advice

8
SHARES

NICE in the UK and its counterpart – the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice…

advice

NICE, the UK’s cost-effectiveness regulator, and its Canadian counterpart have launched a project that focuses on offering parallel scientific advice to the life science industry.

 

SPACES ARE FILLING FAST – SECURE YOURS!


Rapid sterility testing is no longer optional for advanced therapies – it’s becoming operationally essential. Join this webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing

18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

The session will discuss future trends in sterility testing and showcase successful rapid sterility testing in cell and gene therapy products, demonstrating practical applications and benefits.

Register now to join live or for free access to the on-demand recording if you can’t make the date

The Canadian Agency for Drugs and Technology in Health and NICE have collaborated to help drug developers gather cost-effectiveness data during the process of a clinical trial.

The scientific advice that will be given will look to help companies develop evidence that can demonstrate the value of a new treatment. Using expert opinions from a range of contributors including clinicians, health economists and patient representatives, the agencies aim to provide detailed feedback on plans from numerous companies to generate clinical and economic evidence.

The government organisations, from the UK and Canada, both evaluate new treatments using similar methods, and as such have much in common. These organisations value the opportunity for early engagement with companies that target markets in Canada and the UK. This advice should help companies prepare for future health technology assessments, by answering questions that may arise, and providing a key insight into clinical and health economic development plans.

Jeanette Kusel, Director of NICE Scientific Advice said, “We recognise the inherent difficulties faced by developers in designing clinical trial programmes that meet the precise requirements of multiple international markets. This new collaboration with CADTH uses the synergies between the English and Canadian systems and provides companies with comprehensive and practical advice from both countries through a single, streamlined process.”

“This exciting new international collaboration between two established HTA bodies will help pharmaceutical companies develop relevant evidence for CADTH and NICE while streamlining the process of obtaining advice in two distinct markets,” said Dr Michelle Mujoomdar, Acting Vice President, Evidence Standards, CADTH.

Applications from pharmaceutical companies for parallel scientific advice are now being accepted by the agencies.

 
Share via
Share via